Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women

被引:20
作者
Walle, T
Fagan, TC
Walle, UK
Topmiller, MJ
机构
[1] UNIV ARIZONA,COLL MED,DEPT MED,TUCSON,AZ
[2] UNIV ARIZONA,COLL MED,DEPT PHARMACOL,TUCSON,AZ
关键词
ethinyloestradiol; propranolol; metabolism; women; oral contraceptives;
D O I
10.1046/j.1365-2125.1996.03097.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The metabolism of a single 80 mg oral dose of propranolol was determined in nine young women before and after administration of ethinyloestradiol alone (EE(2)) or in combination with norethindrone (OC). 2 Whereas the total clearance of propranolol (2713 +/- 404 ml min(-1) (mean +/- s.e.mean)) was not significantly altered by either EE(2) (3365 +/- 347 ml min(-1)) or the combined OC (2905 +/- 345 ml min(-1)), significant changes in all three primary metabolic pathways were observed. 3 The clearance through side-chain oxidation decreased from 345 +/- 55 ml min(-1) to 262 +/- 33 ml min(-1) after EE(2) (P < 0.05). A similar reduction of cytochrome P450 metabolism by EE(2) has been observed for other drugs. 4 The clearance through glucuronidation increased from 364 +/- 61 ml min(-1) to 625 +/- 117 ml min(-1) after EE(2) (P < 0.01). Similar stimulation of glucuronic acid conjugation by EE(2) has also been observed for other drugs. 5 The clearance through ring oxidation increased from 697 +/- 109 ml min(-1) to 1280 +/- 162 ml min(-1) after EE(2) (P < 0.01). This observation appears to be a novel finding with EE(2) and cytochrome P450 metabolism. 6 The treatment with OC produced changes in propranolol's metabolic clearances which were qualitatively similar to those generated by EE(2).
引用
收藏
页码:305 / 309
页数:5
相关论文
共 27 条
[1]   IMPAIRMENT OF CAFFEINE CLEARANCE BY CHRONIC USE OF LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVES [J].
ABERNETHY, DR ;
TODD, EL .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (04) :425-428
[2]  
[Anonymous], 1991, Understanding Biostatistics
[3]   GENDER-RELATED DIFFERENCES IN XENOBIOTIC METABOLISM [J].
BONATE, PL .
JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (08) :684-690
[4]  
DERAY G, 1987, LANCET, V1, P158
[5]  
FIELD B, 1979, CLIN PHARMACOL THER, V25, P196
[6]  
FUJITA S, 1993, J PHARMACOL EXP THER, V264, P226
[7]  
GUENGERICH FP, 1988, MOL PHARMACOL, V33, P500
[8]  
KATO R, 1974, DRUG METAB REV, V3, P1
[9]   THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PROPRANOLOL [J].
LENNARD, MS ;
JACKSON, PR ;
FREESTONE, S ;
TUCKER, GT ;
RAMSAY, LE ;
WOODS, HF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (06) :679-685
[10]   ONE YEAR STUDY OF AN ESTROGEN-DOMINANT ORAL-CONTRACEPTIVE ON SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN-A-I AND A-II AND HEPATIC-MICROSOMAL FUNCTION [J].
LUOMA, PV ;
HEIKKINEN, JE ;
EHNHOLM, C ;
YLOSTALO, PR .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 31 (05) :563-567